Reliable Performance of mALBI Grade-Based Risk Models for Predicting the Prognosis of Patients With Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab as First-Line Treatment: Comparative Analysis of 13 Risk Models

Hepatology

Liver decompensation in patients with hepatocellular carcinoma treated with Atezolizumab plus Bevacizumab: a real-life study

Clin Gastroenterol Hepatol

Stella L, Pallozzi M, Cerrito L, Santopaolo F, Tovoli F, Hollande C, Sidali S, Stefanini B, Campani C, Pellegrini E, Cabibbo G, Marra F, Piscaglia F, Gasbarrini A, Pompili M, Bouattour M, Ponziani FR

doi: 10.1016/j.cgh.2024.12.028

Gastrointestinal CancerHepatology

Non-invasive risk-based surveillance of hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease

Gut

Lai JC, Yang B, Lee HW, Lin H, Tsochatzis EA, Petta S, Bugianesi E, Yoneda M, Zheng MH, Hagström H, Boursier J, Calleja JL, Goh GB, Chan WK, Gallego-Duràn R, Sanyal AJ, de Lédinghen V, Newsome PN, Fan JG, Castera L, Lai M, Fournier-Poizat C, Wong GL, Pennisi G, Armandi A, Nakajima A, Liu WY, Shang Y, Saint-Loup M, Llop E, Teh KKJ, Lara-Romero C, Asgharpour A, Mahgoub S, Chan MS, Canivet CM, Romero-Gómez M, Kim SU, Wong VW, Yip TC

doi: 10.1136/gutjnl-2025-334981

Gastrointestinal Cancer

First-Line Tislelizumab Plus Chemotherapy for Advanced Gastric Cancer with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-305

Adv Ther

Moehler M, Oh DY, Kato K, Arkenau T, Tabernero J, Lee KW, Rha SY, Hirano H, Spigel D, Yamaguchi K, Wyrwicz L, Disel U, Pazo-Cid RA, Fornaro L, Xu Y, Sheng T, Yang S, Kadva A, Cruz-Correa M, Xu RH

doi: 10.1007/s12325-025-03133-7

Gastrointestinal Cancer

Hepatocellular Carcinoma Etiology Drives Survival Outcomes: A Population-Based Analysis

Cancer Epidemiol Biomarkers Prev

Cranford HM, Jones PD, Wong RJ, Liu Q, Kobetz EN, Reis IM, Koru-Sengul T, Pinheiro PS

doi: 10.1158/1055-9965.EPI-24-0626

Gastrointestinal Cancer

Immune-related Adverse Events are Associated with Improved Outcomes after Immune Checkpoint Inhibitor Treatment in Hepatocellular Carcinoma: A Systematic Review and Meta-analysis

Am J Gastroenterol

Hwang SY, Rezaee-Zavareh MS, Attia AM, Kaymen EA, Tran N, Abou-Alfa GK, Parikh ND, Singal AG, Yang JD

doi: 10.14309/ajg.0000000000003546

Gastrointestinal CancerHepatology

CiThroModel Improves Prediction of Symptomatic Venous Thromboembolism in Hospitalized Patients With Cirrhosis Without Hepatocellular Carcinoma

United European Gastroenterol J

Zanetto A, Vitale A, Pelizzaro F, Simeon V, Campello E, Turco L, Balcar L, Russo FP, Burra P, Simioni P, Senzolo M

doi: 10.1002/ueg2.12758

ColonoscopyGastrointestinal Cancer

A predictive model based on quantitative fecal immunochemical test can stratify the risk of CRC in an organized screening program

Clin Gastroenterol Hepatol

Frazzoni L, Pecere S, Hassan C, Fuccio L, Del Vecchio LE, Fabbri C, Arrigoni A, Cassoni P, Mazzucco D, Orione L, Gibiino G, Repici A, Spada C, Iacopini F, Senore C, Antonelli G

doi: 10.1016/j.cgh.2024.09.036

Inflammatory Bowel Disease

Predictive modeling to evaluate long-term treatment effectiveness of darvadstrocel in patients with complex perianal fistulas in Crohn's disease

BMC Gastroenterol

Karki C, Hantsbarger G, Turkstra E, Fenu E, Genenz K, Gilaberte I, Panés J

doi: 10.1186/s12876-024-03513-3

Inflammatory Bowel Disease

Clinical outcomes after first-line anti-TNF treatment of patients with inflammatory bowel disease - a prospective multicenter cohort study

J Crohns Colitis

Zhao M, Larsen L, Dige A, Poulsen A, Lo B, Attauabi M, Dige Ovesen P, Wewer MD, Christiansen D, Hvas CL, Petersen AM, Bendtsen F, Seidelin J, Burisch J

doi: 10.1093/ecco-jcc/jjae192

Related content

Liver decompensation in patients with hepatocellular carcinoma treated with Atezolizumab plus Bevacizumab: a real-life study

Non-invasive risk-based surveillance of hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease

First-Line Tislelizumab Plus Chemotherapy for Advanced Gastric Cancer with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-305

Hepatocellular Carcinoma Etiology Drives Survival Outcomes: A Population-Based Analysis

Immune-related Adverse Events are Associated with Improved Outcomes after Immune Checkpoint Inhibitor Treatment in Hepatocellular Carcinoma: A Systematic Review and Meta-analysis

CiThroModel Improves Prediction of Symptomatic Venous Thromboembolism in Hospitalized Patients With Cirrhosis Without Hepatocellular Carcinoma

A predictive model based on quantitative fecal immunochemical test can stratify the risk of CRC in an organized screening program

Predictive modeling to evaluate long-term treatment effectiveness of darvadstrocel in patients with complex perianal fistulas in Crohn's disease

Clinical outcomes after first-line anti-TNF treatment of patients with inflammatory bowel disease - a prospective multicenter cohort study